BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp. (BCT.TO) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
bct.to · pe ratio · data through Jul 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for BriaCell Therapeutics Corp. (BCT.TO) measures how much investors pay for each dollar of the company's trailing earnings. BCT.TO's current PE ratio of N/A is calculated by dividing its stock price of $4.32 by its TTM earnings per share of -$10.57.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-07-31
PE Ratio History
2007 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
BriaCell Therapeutics Corp.You BCT.TO | $8M | N/A | — | -$10.57 |
 Rapid Dose Therapeutics Corp. DOSE.CN | $12M | N/A | — | -$0.04 |
 Gemina Laboratories Ltd. GLAB.CN | $5M | N/A | — | -$0.06 |
 Greenway Greenhouse Cannabis Corporation GWAY.CN | $21M | N/A | — | -$0.02 |
 Hemostemix Inc. HEM.V | $11M | N/A | — | -$0.03 |
 Izotropic Corporation IZO.CN | $19M | N/A | — | -$0.05 |
 Microbix Biosystems Inc. MBX.TO | $37M | N/A | — | -$0.02 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-07-31Latest FY2025 | — | $-62.95 | — | |
2024-07-31 FY2024 | — | $-43.68 | — | |
2023-07-31 FY2023 | — | $-194.97 | — | |
2022-07-31 FY2022 | — | $-259.83 | — | |
2021-07-31 FY2021 | — | $-458.55 | — | |
2020-07-31 FY2020 | — | $-1038.26 | — | |
2019-07-31 FY2019 | — | $-1497.67 | — | |
2018-07-31 FY2018 | — | $-1897.08 | — | |
2017-07-31 FY2017 | — | $-1421.98 | — | |
2016-07-31 FY2016 | — | $-1151.69 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for BriaCell Therapeutics Corp. (BCT.TO) measures how much investors pay for each dollar of the company's trailing earnings. BCT.TO's current PE ratio of N/A is calculated by dividing its stock price of $4.32 by its TTM earnings per share of -$10.57.
Frequently asked questions
BCT.TO pe ratio · 6 questionsBCT.TO's current PE ratio is N/A as of 2026-06-08, based on a stock price of $4.32 and TTM EPS of -$10.57. Data sourced from Financial Modeling Prep via BCT.TO's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · BriaCell Therapeutics Corp. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08